KEYNOTE-042 and the role for single agent pembrolizumab in patients with PD-L1 tumor proportion score 1–49%

Ítems similars

• Can PD-L1 tumor proportion score be used as the key to unlocking the KEYNOTE studies of pembrolizumab in advanced lung cancer?
  per: Piper, Andrew J., et al.
  Publicat: (2019)
• KEYNOTE-042: is lowering the PD-L1 threshold for first-line pembrolizumab monotherapy a good idea?
  per: Pacheco, Jose M.
  Publicat: (2019)
• Keynote 42: Pembrolizumab, PD-L1, and where to draw the line
  per: Isaacs, James, et al.
  Publicat: (2020)
• Keynote-158 study, FDA granted accelerated approval of pembrolizumab for the treatment of patients with advanced PD-L1-positive cervical cancer
  per: Borcoman, Edith, et al.
  Publicat: (2020)
• KEYNOTE-042 rolls back programmed cell death ligand 1 threshold for non-small cell lung cancer pembrolizumab monotherapy without new insight into those deriving benefit
  per: Cummings, Amy Lauren, et al.
  Publicat: (2019)